Fetuin‐A and interleukin‐18 levels in ankylosing spondylitis

Sarı, İ̇smail; Kebapçılar, Levent; Taylan, Ali; Bilgir, Oktay; Kozacı, Didem; Yıldız, Yaşar; Yüksel, Arif; Günay, Necati; Akkoç, Nurullah

doi:10.1111/j.1756-185x.2009.01448.x

Cited by 14 publications

(22 citation statements)

References 23 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we did not detect any correlation between BASRI and fetuin-A. In contrast to previous studies reporting high fetuin-A levels in AS patients, 10 we found low fetuin-A levels similar to studies in RA and FMF patients. 5,17,18 In addition, the negative correlation we showed between CRP and fetuin-A, and the negative correlation with ESR and CRP demonstrated in studies involving chronic kidney failure, cardiovascular disease, and rheumatic diseases indicate that fetuin-A may be a negative acute phase reactant.…”

Section: Discussioncontrasting

confidence: 56%

“…However, we found no correlation between fetuin-A and disease markers such as ESR, BASDAI, BASFI or BASMI. In contrast to Sarı et al, 10 we also assessed patient BASRI indices. However, we did not detect any correlation between BASRI and fetuin-A.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, in the same study, a comparison of fetuin-A levels of patients using biological agents with high disease activity score and peripheral joint involvement revealed no significant difference. Sarı et al 10 suggested that the elevated fetuin-A might be attributed to the disease itself, independently of clinical markers. In our study, we detected lower serum fetuin-A levels in the AS patient group compared to the control group (p=0.001).…”

Section: Discussionmentioning

confidence: 99%

“…That study demonstrated that fetuin-A levels were elevated in AS patients. 10 It is therefore unclear whether fetuin-A is a negative or positive acute phase reactant.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Serum Fetuin-A Level in Patients With Ankylosing Spondylitis and its Relationship With Clinical Parameters

et al. 2015

View full text Add to dashboard Cite

Objectives:This study aims to investigate the association of serum fetuin-A levels with disease activation and clinical parameters in ankylosing spondylitis (AS) patients. Patients and methods: Forty-seven AS patients (30 males, 17 females; mean age 39.7±11.1 years; range 20 to 69 years) and 30 healthy controls (14 males, 16 females; mean age 42.0±11.5 years; range 19 to 63 years) were included in the study. Erythrocyte sedimentation rate, C-reactive protein, Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Radiology Index, and Bath Ankylosing Spondylitis Metrology Index were used in the assessment of AS. Serum fetuin-A levels were measured using ELISA. Results: Mean serum fetuin-A values in AS patients (984±203 ng/mL) were significantly lower compared to controls (1156±218 ng/mL) (p=0.001). While a statistically significant negative correlation was detected in AS patients between fetuin-A values and C-reactive protein (p=0.009, r=-0.377), no significant correlation was detected between erythrocyte sedimentation rate, Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Metrology Index, Bath Ankylosing Spondylitis Functional Index or Bath Ankylosing Spondylitis Radiology Index parameters and fetuin-A. Conclusion: Serum fetuin-A levels in AS patients were lower than the control group. However, further research is required to establish the role of serum fetuin-A levels as a surrogate marker of disease activity.

show abstract

Section: Discussioncontrasting

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…That study demonstrated that fetuin-A levels were elevated in AS patients. 10 It is therefore unclear whether fetuin-A is a negative or positive acute phase reactant.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Serum Fetuin-A Level in Patients With Ankylosing Spondylitis and its Relationship With Clinical Parameters

et al. 2015

View full text Add to dashboard Cite

show abstract

“…However, available data on this subject are still limited and additional information is required to clarify the underlying mechanisms of new bone formation in AS. In a recent study, we reported increased serum fetuin-A levels compared with controls 4. Considering the role of fetuin-A in the regulation of calcified matrix metabolism 5, we designed this study with the primary objective of comparing the fetuin-A levels in AS patients with and without syndesmophytes versus healthy controls.…”

Section: Introductionmentioning

confidence: 99%

Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study

Tüylü¹,

Sarı²,

Solmaz³

et al. 2014

Clinics

Self Cite

View full text Add to dashboard Cite

OBJECTIVES:New bone formation is one of the hallmark characteristics of ankylosing spondylitis, which is thereby associated with syndesmophytes. Fetuin-A is a molecule that is abundantly found in calcified tissues and it shows high affinity for calcium phosphate minerals and related compounds. Considering the role of fetuin-A in the regulation of calcified matrix metabolism, we compared the fetuin-A levels in ankylosing spondylitis patients with syndesmophytes with those in patients without syndesmophytes and in healthy controls. We also studied other biomarkers that are thought to be related to syndesmophytes.METHODS:Ninety-four patients (49 patients without syndesmophytes, 67.3% male, 40.7±8.7 years; 45 patients with syndesmophytes, 71.1% M, 43.9±9.9 years) and 68 healthy controls (44.2±10.6 years and 70.6% male) were included in this study. Syndesmophytes were assessed on the lateral radiographs of the cervical and lumbar spine. The serum levels of fetuin-A, dickkopf-1, sclerostin, IL-6, high-sensitivity C-reactive protein and bone morphogenetic protein-7 were measured with an enzyme-linked immunosorbent assay.RESULTS:Patients with syndesmophytes had significantly higher levels of fetuin-A compared with patients without syndesmophytes and controls (1.16±0.13, 1.05±0.09 and 1.08±0.13 mg/ml, respectively). However, fetuin-A was not different between the patients without syndesmophytes and controls. Bone morphogenetic protein-7 was significantly lower; dickkopf-1 was significantly higher in patients with ankylosing spondylitis compared with controls. The sclerostin concentrations were not different between the groups. In regression analysis, fetuin-A was an independent, significant predictor of syndesmophytes.CONCLUSION:Our results suggest that fetuin-A may a role in the pathogenesis of bony proliferation in ankylosing spondylitis.

show abstract

Evaluation of various endothelial biomarkers in ankylosing spondylitis

et al. 2011

View full text Add to dashboard Cite

Atherosclerosis has been shown to be increased in chronic inflammatory diseases including ankylosing spondylitis (AS). Impaired endothelial function, the first step in atherosclerosis, may be reflected by changes in various endothelial biomarkers of hemostasis and the release of several cellular adhesion molecules or cytokines. In this study, we investigated changes in the levels of various possible markers with regard to disease activity and treatment regimen with/without anti-TNF-α drugs. Fifty-six AS patients (44 males) and 27 controls (19 males) with no known cardiovascular risk factors were included in the study. Spinal mobility was assessed by the Bath Ankylosing Spondylitis Metrology Index, and patients were evaluated with the Bath Ankylosing Spondylitis Functional Index and the Bath Ankylosing Spondylitis Disease Activity Index. Cytokines and various endothelial biomarkers were measured in serum samples using commercially available ELISA kits. Age, sex, BMI, waist circumference, fasting glucose, MAP, lipids are all similar between patients and controls. von Willebrand factor (vWF), soluble thrombomodulin (sTM), and urotensin (UT-II) were found to be significantly higher in the sera of the patients compared to the controls. Treatment with anti-TNF-α compared to conventional therapy and disease activity in AS patients seemed to have no effect on the blood levels of UT-II, sTM, CD146, vWF, plasminogen activator inhibitor-1, tissue plasminogen activator, or the thrombin-antithrombin complex. The increased UT-II, sTM, and vWF in AS patient sera regardless of treatment and disease activity suggest an increased tendency for atherosclerosis.

show abstract

Fetuin‐A and interleukin‐18 levels in ankylosing spondylitis

Abstract: Fetuin-A and IL-18 levels seem to be increased in AS patients regardless of disease activity and treatment type.

Cited by 14 publications

References 23 publications

Serum Fetuin-A Level in Patients With Ankylosing Spondylitis and its Relationship With Clinical Parameters

Serum Fetuin-A Level in Patients With Ankylosing Spondylitis and its Relationship With Clinical Parameters

Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study

Evaluation of various endothelial biomarkers in ankylosing spondylitis

Contact Info

Product

Resources

About